Basic Information
TIDACT INJECTION 150 mg/ml
INJECTION
Regulatory Information
SIN07759P
July 1, 1994
Prescription Only
Therapeutic
INTRAVENOUS, INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ01FF01
Company Information
YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
Active Ingredients
Strength: 150 mg/ml
Detailed Information
Contraindications
**Contraindications:** 1. History of gastrointestinal disease, especially ulcerative colitis, regional enteritis, and antibiotic-associated colitis. Clindamycin may cause pseudomembranous colitis. 2. Severe hepatic function impairment. Half-life of Clindamycin is prolonged in this condition, therefore may require dosage adjustment. 3. Hypersensitivity to Lincomycins and doxorubicin. 4. Severe renal function impairment may require reduction of dosage.
Indication Information
**Indications:** For the treatment of serious infections due to susceptible strains of Staphylococci, Streptococci, Pneumococci, and anaerobic bacteria.